Robert Bloder is listed as a director on 4 SEC Form D filings by 1 issuer between Jul 2022 and Jul 2026: ASCENDIA PHARMACEUTICALS, INC. (North Brunswick, NJ — other health care — 2022–2026; $5M reported sold to 9 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside James Gale (4 shared filings), Jingjun Huang (4 shared filings), Theron Odlaug (4 shared filings), Shoufeng Li (3 shared filings), Colin Foster (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Robert Bloder and found 3 differences: Form D filed 28 days after the first sale; Industry group changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.